Network News
Basel, Switzerland, 8 May 2026 – Today, Lonza Group Ltd held its Annual General Meeting (AGM), led by the Chair of the Board of Directors, Jean-Marc Huët. 62.58% of the share capital was represented at the AGM, with attending and represented shareholders collectively holding a total of 43,948,027 shares. All Board members standing for re-election were re-elected, each for a further term in office until the completion of the AGM 2027. The following Board members stood for re-election: Jean-Marc Huët, Juan […]
read more
A single swab is sufficient: Study paves the way for simplified tuberculosis diagnosis
Led by researchers from Heidelberg Faculty of Medicine at Heidelberg University and the University of California, San Francisco (USA), an international research team has evaluated a novel approach for the diagnosis of pulmonary tuberculosis. The method enables detection of Mycobacterium tuberculosis without laboratory infrastructure, within a markedly shorter time frame than conventional diagnostics, and using […]
read more
Hella Bühler Prize Awarded to DKFZ Researcher Angelika Feldmann
For her groundbreaking research on the regulation of gene activity, Angelika Feldmann has been awarded the 2026 Hella Bühler Prize, which comes with a grant of €100,000. Presented by Heidelberg University, the award is intended for young researchers in the Heidelberg research community who have already distinguished themselves through outstanding scientific achievements in cancer research. […]
read more
New Nature Publication by Akribion Therapeutics GmbH: RNA-triggered cell killing with CRISPR–Cas12a2
Scholz, P., Thompson, J., Crosby, K.T. et al. RNA-triggered cell killing with CRISPR–Cas12a2. Nature (2026). https://doi.org/10.1038/s41586-026-10466-y Abstract Selectively eradicating target cells on the basis of their genetic or transcriptional identity remains important in basic research, medicine, biotechnology and agriculture1,2,3. For applications involving bacteria, CRISPR nucleases offer promising options due to their ability to enact RNA-guided counterselection4,5,6,7; however, using these […]
read more
VectorBuilder Secures European Patent for MiniVec™, a Plasmid Backbone Advancing Safety and Manufacturability in Genetic Medicine
Small by design, built for the demands of modern genetic medicine across gene therapy, cell therapy, and vaccines Chicago, IL – May 5, 2026 – VectorBuilder, a global leader in gene delivery technologies and CDMO services, today announced that its MiniVec™ plasmid system has been granted a European patent, marking a significant milestone for the company’s proprietary plasmid DNA technology […]
read more
Nobel-Potential Discovery from VectorBuilder Scientists Reveals Fundamental Mechanisms of Development
Chicago, April 21, 2026 – One of the most fundamental questions in biology is how a single fertilized egg produces the diverse cell types making up the body – from neurons and skin to muscle and blood – that bear the same genetic blueprint but distinct expression patterns. Now, a research team lead by Dr. Bruce Lahn, […]
read more
AGC Biologics Wins 2026 Fierce Outsourcing Award for Leadership in Regulatory and Quality Compliance
Global CDMO recognized for exceptional quality systems and regulatory track record; named finalist in Excellence in Client Service & Partnership and Manufacturing Operations categories SEATTLE – April 27, 2026 – AGC Biologics, your friendly CDMO expert, is the 2026 recipient of the Fierce Outsourcing Award for Leadership in Regulatory and Quality Compliance. The award recognizes the […]
read more
Molecular research: When speed meets precision
KIMMDY software visualizes biological processes in motion – conceived and originally developed at HITS, refined and published at the Max Planck Institute for Polymer Research in Mainz Within biological cells, molecules are constantly in motion. Investigating these motions, however, is still difficult, due to the fact that these processes occur on very small length and time […]
read more
Brain metastases from breast cancer: Immune cell patterns could improve treatment decisions
Brain metastases are among the most serious complications of advanced breast cancer. Researchers from Heidelberg University’s Faculty of Medicine, the German Cancer Research Center (DKFZ), and Heidelberg University Hospital (UKHD) have conducted a detailed study of the body’s immune cells in the brain tissue surrounding these metastases. Their findings revealed that certain distribution patterns of […]
read more
